基于口服免疫耐受原理的人肿瘤小鼠荷瘤模型的建立

目的: 基于口服免疫耐受原理,建立针对人特异性免疫耐受的人类肿瘤小鼠荷瘤模型。方法: 将90只昆明种小鼠随机分为肿瘤模型组、无关肿瘤对照组和空白对照组,每组30只。 分别以人肝癌HepG2细胞系、人卵巢癌3AO细胞系和等体积生理盐水连续灌胃7 d,然后于背部皮下注射人肝癌HepG2细胞系。观察肿瘤形成情况,测量不同时间段肿瘤组织的大小,并对肿瘤组织作病理切片于光学显微镜下观察。结果: 人肝癌HepG2细胞系能在HepG2细胞灌胃小鼠的皮下成活并形成肿瘤,致瘤率可达90％(27/30);而生理盐水对照组和无关肿瘤对照组的小鼠均未成瘤。局部组织经病理切片,HE染色,在肿瘤模型组可见肿瘤组织,而无关肿瘤对照组和生理盐水对照组可见明显的肿瘤细胞死亡后的残留痕迹。结论: 通过口服肿瘤细胞产生特异性免疫耐受,成功地建立了相应的人肿瘤小鼠模型。

Establishment of a mouse model of human tumor based on principle of oral tolerance

Objective: To establish a mouse model of human tumor specific immune tolerance based on principle of oral tolerance. Methods: Ninety mice were randomly divided into three groups: blank control group, irrelevant tumor control group and experimental tumor model group, thirty in each group. The mice of three groups were received intragastric administration of normal saline, human ovarian cancer cell line 3AO and human hepatoma cell line HepG2 cells for 7 days, respectively. Then, all mice received subcutaneous injection of HepG2 cells in the back skin. The time course of the tumor incidence were recorded and the size of tumor were determined by slide caliper. The histological examination of sections of tumor tissues were evaluated by optical microscope. Results: HepG2 cells in mice from experimental tumor model group survived and developed into tumor after subcutaneous injection of HepG2 cells. The tumor incidence was 90％ (27/30). There was no tumor formation in the mice of blank control group and irrelevant tumor control group. Obviously pathologic changes were found in tumor tissue sections with HE staining, while some debris of death tumor cells were found in mice from control group and irrelevant tumor control group. Conclusion: The mouse model of human tumor was established successfully by intragastric administration of HepG2 cells through induction of specific immune tolerance.